Histrelin Implants for Suppression of Puberty in Youth with Gender Dysphoria: A Comparison of 50 mcg/Day (Vantas) and 65 mcg/Day (SupprelinLA).

Olson-Kennedy J, Streeter LH, Garofalo R, Chan YM, Rosenthal SM

Transgender health15 Feb 2021Cited by 16 (Europe PMC)

PMID33644320PMCIDPMC7906230DOI10.1089/trgh.2020.0055PepBankPUB-33644320

Summary

Purpose: Development of incongruent secondary sex characteristics in transgender youth can intensify or trigger the onset of gender dysphoria. Guidelines from professional organizations recommend gonadotropin-releasing hormone agonists, including histrelin implants (Vantas and SupprelinLA) to suppress endogenous puberty. Although Vantas does not have a pediatric indication, it is anecdotally being used in pediatric gender centers throughout the United States because of its substantially lower cost. This retrospective study aimed to determine if both implants were effective in suppressing the hypothalamic-pituitary-gonadal axis in early-to-mid pubertal youth with gender dysphoria. Methods: Youth with gender dysphoria receiving care at the Center for Transyouth Health and Development at Children's Hospital Los Angeles (CHLA) or participants from an ongoing observational trial with a histrelin implant placed for pubertal suppression at Tanner stage 2 or 3 were included. Sex steroid (testosterone or estradiol) and gonadotropin measurements at baseline (T0) and then 2 to 12 months following implant placement (T1) were abstracted from medical records. Results: Of the 66 eligible participants, 52% were designated female at birth. Most participants were white (60.6%). Twenty participants (30.3%) had a Vantas implant and 46 (69.7%) had a SupprelinLA implant. Mean age of insertion was 11.3 years. Gonadotropin and sex steroid levels were significantly decreased at T1 (2-12 months after insertion of implant), with no differences between implants. Conclusion: These results indicate that both implants are effective in suppressing puberty in early-to-mid pubertal youth with gender dysphoria. These data may inform decisions about insurance coverage of Supprelin and/or Vantas for youth with gender dysphoria.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanObservational studyEfficacy outcome
In youth with gender dysphoria, gonadotropin levels decreased significantly after histrelin implantation.
In plain wordsIn youth with gender dysphoria, hormone levels decreased significantly after histrelin implantation compared with baseline.
Peptide
Histrelin
Outcome
DecreaseGonadotropin suppression
Study
n = 66
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated · 2 to 12 monthsAs given in this study (human).
Source sentences
Summary
Gonadotropin and sex steroid levels were significantly decreased at T1 (2-12 months after insertion of implant), with no differences between implants.
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective study aimed to determine if both implants were effective in suppressing the hypothalamic-pituitary-gonadal axis in early-to-mid pubertal youth with gender dysphoria.
Summary · context
Sex steroid (testosterone or estradiol) and gonadotropin measurements at baseline (T0) and then 2 to 12 months following implant placement (T1) were abstracted from medical records.
Show in the study text Report a problemFND-3364432001
02HumanObservational studyEfficacy outcome
In youth with gender dysphoria, sex steroid levels decreased significantly after histrelin implantation.
In plain wordsIn youth with gender dysphoria, sex steroid levels decreased significantly after histrelin implantation compared with baseline.
Peptide
Histrelin
Outcome
DecreaseSex steroid suppression
Study
n = 66
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated · 2 to 12 monthsAs given in this study (human).
Source sentences
Summary
Gonadotropin and sex steroid levels were significantly decreased at T1 (2-12 months after insertion of implant), with no differences between implants.
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective study aimed to determine if both implants were effective in suppressing the hypothalamic-pituitary-gonadal axis in early-to-mid pubertal youth with gender dysphoria.
Summary · context
Sex steroid (testosterone or estradiol) and gonadotropin measurements at baseline (T0) and then 2 to 12 months following implant placement (T1) were abstracted from medical records.
Show in the study text Report a problemFND-3364432002
03HumanObservational studyEfficacy outcome
In youth with gender dysphoria, gonadotropin levels did not differ between SupprelinLA and Vantas histrelin implants.
In plain wordsIn youth with gender dysphoria, gonadotropin levels did not differ between SupprelinLA and Vantas histrelin implants.
Peptide
Histrelin
Outcome
No significant changeGonadotropin levels between implants
Study
n = 66
Comparator
Vantas histrelin implant
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
65 mcg/day (SupprelinLA) versus 50 mcg/day (Vantas) · 2 to 12 monthsAs given in this study (human).
Source sentences
Summary
Gonadotropin and sex steroid levels were significantly decreased at T1 (2-12 months after insertion of implant), with no differences between implants.
4 context sentences(design, population, supporting numbers)
Summary · context
Twenty participants (30.3%) had a Vantas implant and 46 (69.7%) had a SupprelinLA implant.
Title · context
Histrelin Implants for Suppression of Puberty in Youth with Gender Dysphoria: A Comparison of 50 mcg/Day (Vantas) and 65 mcg/Day (SupprelinLA).
Summary · context
This retrospective study aimed to determine if both implants were effective in suppressing the hypothalamic-pituitary-gonadal axis in early-to-mid pubertal youth with gender dysphoria.
Summary · context
Sex steroid (testosterone or estradiol) and gonadotropin measurements at baseline (T0) and then 2 to 12 months following implant placement (T1) were abstracted from medical records.
Show in the study text Report a problemFND-3364432003
04HumanObservational studyEfficacy outcome
In youth with gender dysphoria, sex steroid levels did not differ between SupprelinLA and Vantas histrelin implants.
In plain wordsIn youth with gender dysphoria, sex steroid levels did not differ between SupprelinLA and Vantas histrelin implants.
Peptide
Histrelin
Outcome
No significant changeSex steroid levels between implants
Study
n = 66
Comparator
Vantas histrelin implant
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
65 mcg/day (SupprelinLA) versus 50 mcg/day (Vantas) · 2 to 12 monthsAs given in this study (human).
Source sentences
Summary
Gonadotropin and sex steroid levels were significantly decreased at T1 (2-12 months after insertion of implant), with no differences between implants.
4 context sentences(design, population, supporting numbers)
Summary · context
Twenty participants (30.3%) had a Vantas implant and 46 (69.7%) had a SupprelinLA implant.
Title · context
Histrelin Implants for Suppression of Puberty in Youth with Gender Dysphoria: A Comparison of 50 mcg/Day (Vantas) and 65 mcg/Day (SupprelinLA).
Summary · context
This retrospective study aimed to determine if both implants were effective in suppressing the hypothalamic-pituitary-gonadal axis in early-to-mid pubertal youth with gender dysphoria.
Summary · context
Sex steroid (testosterone or estradiol) and gonadotropin measurements at baseline (T0) and then 2 to 12 months following implant placement (T1) were abstracted from medical records.
Show in the study text Report a problemFND-3364432004

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.